Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.
Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01721044?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
